Metastatic osteosarcoma, patterns of care and outcomes of patients in a real‐life national setting over a decade
International Journal of Cancer · 2026
DOI: 10.1002/ijc.70157 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift International Journal of Cancer, 2026. Verfasst von Mathilde Reich und 24 weiteren Autor:innen. Beteiligte Einrichtung: Medical Oncology Department, Centre Hospitalier Universitaire Cochin, APHP, Paris, France. Hauptthemen laut MEDLINE: Osteosarcoma, Bone Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 31 Literaturangaben. Gefördert von: Bayer, Institut National Du Cancer.
Abstract (Originalsprache)
Metastatic osteosarcoma (MOS) has a poor prognosis, and few treatment options. This multicentre observational study provides real‐world data on treatment patterns of patients with MOS in France. The primary objective was to describe treatment modalities of patients with MOS aged ≥12 years treated in 11 reference network centers. Secondary objectives were to assess time to next treatment (TTNT), overall survival (OS) and prognostic factors for TTNT and OS. From 2008 to 2018, 262 patients with MOS were included; 88 patients were metastatic at diagnosis, and 174 patients had a metastatic relapse. Median age at diagnosis was 26 (12–86). A total of 227 (86.6%) patients received systemic treatment in the metastatic setting, and 75 (28.6%) patients received more than two lines. Overall, 153 (58.4%) patients underwent at least a loco‐regional procedure, and 50 patients (19.1%) participated in a clinical trial in the metastatic setting. Median OS from metastasis diagnosis was 21.5 months [95% CI 18.9–27.0], 23.0 months [95% CI 15.0–31.1] in the synchronous cohort, and 21.4 months [95% CI 18.7–29.7] in the metachronous cohort. Median TTNT was 8.2 months [95% CI 6.7–9.9], 5.7 months [95% CI 4.2–7.2], 3.7 months [95% CI 3.0–4.3], and 2.9 months [95% CI 1.8–3.9] in first, second, third, and fourth line. It was 7.6 months [95% CI 5.1–12.5], 6 months [95% CI 3.6–8.7], and 4.8 months [95% CI 2.9–7.5] for tyrosine kinase inhibitors such as regorafenib or cabozantinib in first, second, and third line. In MOS, the benefit of chemotherapy after first line is limited. TKIs show encouraging activity from first line. Inclusion in clinical trials should be prioritized.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Medical Oncology Department, Centre Hospitalier Universitaire Cochin, APHP, Paris, France.
- Inserm CIC1401, Clinical and Epidemiological Research Unit, Institut Bergonié, Bordeaux, France.
- BPH, Epicene team, UMR 1219, University of Bordeaux, Bordeaux, France.
- Medical Oncology Department, Institut Gustave Roussy, Villejuif, France.
- Clinical and Epidemiological Research Unit, Centre Hospitalier Universitaire de Nantes, France.
- Clinical and Epidemiological Research Unit, Centre Léon Bérard, Lyon, France.
ORCID-Profile: Sophie Piperno-Neumann, Pascaline Boudou-Rouquette, Maud Toulmonde
Förderung
- Bayer
- Institut National Du Cancer
Zitieren
APA
Reich, M., Dinart, D., Bellio, H., Berchoud, J., Jean-Denis, M., Bonneau, M., Winter, S., Brunet, M., Duong, R., Nannini, S., Gantzer, J., Narciso, B., Piperno-Neumann, S., Valentin, T., Marec-Berard, P., Brahmi, M., Bompas, E., Anract, P., Goldwasser, F., …, & Toulmonde, M. (2026). Metastatic osteosarcoma, patterns of care and outcomes of patients in a real‐life national setting over a decade. International Journal of Cancer. https://doi.org/10.1002/ijc.70157
Vancouver
Reich M, Dinart D, Bellio H, Berchoud J, Jean-Denis M, Bonneau M, et al. Metastatic osteosarcoma, patterns of care and outcomes of patients in a real‐life national setting over a decade. International Journal of Cancer. 2026. doi:10.1002/ijc.70157
BibTeX
@article{Reich2026,
author = {Reich, Mathilde and Dinart, Derek and Bellio, Hélène and Berchoud, Juliane and Jean-Denis, Myriam and Bonneau, Maeva and Winter, Sarah and Brunet, Maxime and Duong, Romain and Nannini, Simon and Gantzer, Justine and Narciso, Berengère and Piperno-Neumann, Sophie and Valentin, Thibaud and Marec-Berard, Perrine and Brahmi, Mehdi and Bompas, Emmanuelle and Anract, Philippe and Goldwasser, François and Perret, Raul and Le Cesne, Axel and Gaspar, Nathalie and Boudou-Rouquette, Pascaline and Bellera, Carine and Toulmonde, Maud},
title = {Metastatic osteosarcoma, patterns of care and outcomes of patients in a real‐life national setting over a decade},
journal = {International Journal of Cancer},
year = {2026},
doi = {10.1002/ijc.70157}
}
EUVIMED